Press releases
Alligator strives to communicate in a structured, transparent and clear manner to all stakeholders. Part of this work includes press releases, which may, for example, concern developments in the project portfolio or other news concerning the company.
2025-07-14 | Alligator Bioscience comments on Henlius dosing first patient in the US in Phase 3 trial of HLX22 in gastric cancer
Downloads
2025-07-10 | Alligator Bioscience AB reports financial results for Q2 2025 and provides a business update
Downloads
2025-06-17 | Alligator receives positive scientific advice from EMA on Phase 3 trial of mitazalimab
Downloads
2025-06-13 | Alligator Bioscience receives FDA endorsement of mitazalimab Phase 3 dose for pancreatic cancer
Downloads
2025-06-03 | Biomarker data from Alligator Bioscience’s OPTIMIZE-1 trial presented at ASCO 2025 Annual Meeting
Downloads
2025-05-26 | Alligator Bioscience AB carries out directed issues to guarantors in connection with exercise of warrants series TO 12
Downloads
2025-05-26 | Alligator Bioscience announces Henlius receives European orphan drug designation for HLX22 in gastric cancer
Downloads
2025-05-23 | Alligator Bioscience presents OPTIMIZE-1 biomarker data at ASCO 2025 Annual Meeting
Downloads
2025-05-21 | Alligator Bioscience AB announces final outcome of exercise of warrants series TO 12
Downloads
2025-05-20 | Alligator Bioscience announces paediatric study waiver for mitazalimab granted by the European Medicines Agency
Downloads
2025-05-20 | Alligator Bioscience AB announces preliminary outcome of exercise of warrants series TO 12
Downloads
2025-05-15 | Last day of trading in warrants series TO 12 in Alligator Bioscience is 15 May 2025
Downloads
2025-05-09 | Alligator Bioscience announces that 85% of the warrant programme TO 12 has been secured and that the outstanding loan has been renegotiated
Downloads
2025-05-09 | Alligator Bioscience completes Phase 3 GMP manufacturing of mitazalimab, remains on track for trial initiation with partner
Downloads
2025-05-07 | Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2025
Downloads
2025-04-28 | Exercise price determined for the exercise of warrants series TO 12 in Alligator Bioscience AB
Downloads
2025-04-24 | Alligator Bioscience AB reports financial results for Q1 2025 and provides a business update
Downloads
2025-04-23 | Alligator Bioscience announces initiation of HLX22 Phase 2 trial in breast cancer by Shanghai Henlius Biotech, Inc.
Downloads
2025-04-01 | Alligator Bioscience determines record date for reverse share split of ordinary shares and reminds of the recalculation of warrants
Downloads
2025-03-20 | Alligator Bioscience Announces FDA Orphan Drug Designation for HLX22/AC101 in Gastric Cancer
Downloads
2025-02-26 | Alligator Bioscience Announces Continued Encouraging Overall Survival Benefit for Mitazalimab
Downloads
2025-02-25 | The Board of Directors of Alligator Bioscience propose a reverse share split of ordinary shares
Downloads
2025-02-24 | Alligator Bioscience’s rights issue is registered – conversion of BTU into shares and warrants
Downloads
2025-02-20 | Alligator Bioscience carries out a directed issue of units to guarantors and a directed issue of warrants to Fenja Capital in connection with the completed rights issue
Downloads
2025-02-06 | Alligator Bioscience Successfully Completes End of Phase 2 Interaction with FDA For Mitazalimab
Downloads
2025-01-29 | Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer
Downloads
2025-01-27 | Alligator Bioscience Reports Incremental Overall Survival Benefit of mitazalimab combined with mFOLFIRINOX based on Literature-based Indirect Comparison of Outcomes
Downloads
2025-01-24 | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
Downloads
2025-01-22 | Alligator Bioscience AB reports full year financial results for 2024 and for Q4 2024 and provides a business update
Downloads
2025-01-16 | Alligator Bioscience Announces Positive Outcome of Regulatory Interactions on Phase 3 CMC activities
Downloads
2024-12-20 | Alligator Bioscience AB announces outcome of exercise of warrants series TO 9
Downloads
2024-12-13 | Last day of trading in warrants series TO 9 in Alligator Bioscience AB is 13 December 2024
Downloads
2024-12-04 | Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial
Downloads
2024-12-03 | Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program
Downloads
2024-12-02 | Exercise price determined for the exercise of warrants series TO 9 in Alligator Bioscience AB
Downloads
2024-12-02 | Alligator Bioscience carries out a rights issue of units of approximately SEK 280 million and raises bridge loans
Downloads
2024-12-02 | Alligator sharpens focus on mitazalimab and announces cost reduction program to maximize long-term value creation
Downloads
2024-11-19 | Alligator announces sale of future financial commitments for two bispecific antibodies to Orion Corporation
Downloads
2024-11-11 | First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
Downloads
2024-11-06 | Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer at SITC 2024
Downloads
2024-10-31 | Nomination Committee appointed in respect of AGM 2025 in Alligator Bioscience AB
Downloads
2024-10-30 | Alligator Bioscience to Participate in Upcoming Scientific and Investor Conferences in Q4 2024
Downloads
2024-10-29 | Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
Downloads
2024-10-24 | Alligator Bioscience AB reports financial results for the first 9 months of 2024 and for Q3 2024 and provides a business update
Downloads
2024-09-16 | Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study
Downloads
2024-09-13 | Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024
Downloads
2024-07-11 | Alligator Bioscience AB reports financial results for H1 2024 and Q2 2024 and provides a business update
Downloads
2024-07-10 | Alligator Bioscience Announces Completion of Enrollment in Mitazalimab OPTIMIZE-1 Study
Downloads
2024-06-26 | Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
Downloads
2024-06-25 | Alligator Bioscience announces financing of up to SEK 80 million extending cash runway to Q1 2025
Downloads
2024-06-20 | Alligator Bioscience to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024
Downloads
2024-06-03 | Alligator Bioscience’s Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology
Downloads
2024-05-23 | Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
Downloads
2024-05-21 | Alligator Bioscience’s Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer
Downloads
2024-05-20 | Alligator Bioscience Announces Publication Highlighting Potential of Next-Generation CD40 Agonists in Peer-Reviewed Medical Journal “Expert Opinion on Biological Therapy”
Downloads
2024-05-14 | Alligator Bioscience Announces Initiation of an Investigator-Initiated Initiation of Phase 1 Clinical Study of Intratumoral Mitazalimab in Locally Advanced Pancreatic Cancer
Downloads
2024-05-07 | Bulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2024
Downloads
2024-05-06 | Alligator Bioscience AB reports financial results for Q1 2024 and provides a business update
Downloads
2024-04-26 | Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement
Downloads
2024-04-08 | Alligator Bioscience Announces Two Presentations on Mitazalimab and ATOR-4066 at the AACR Annual Meeting 2024
Downloads
2024-03-26 | Alligator Bioscience Announces Publication Highlighting its RUBY® Bispecific Antibody Format in the Scientific Journal “mAbs”
Downloads
2024-03-15 | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
Downloads
2024-03-07 | Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
Downloads
2024-02-08 | Alligator carries out a rights issue of units of approximately SEK 150.9 million with an over-allotment issue of up to an additional approximately SEK 100.0 million and raises bridge loans
Downloads
2024-02-08 | Alligator Bioscience AB reports full year financial results for 2023 and for Q4 2023 and provides a business update
Downloads
2024-02-08 | Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation
Downloads
2024-01-29 | Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer
Downloads
2024-01-16 | Alligator Bioscience Granted First U.S. Patent for Neo-X-Prime™ Bispecific Antibody ATOR-4066 for Cancer Treatment
Downloads
2023-11-09 | Alligator Bioscience to Participate in Upcoming Industry Conferences in November 2023
Downloads
2023-11-06 | Correction: Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB
Downloads
2023-11-06 | Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB
Downloads
2023-11-03 | Alligator Bioscience Announces Poster Presentation on Neo-X-Prime Bispecific Antibody ATOR-4066 at SITC Annual Meeting 2023
Downloads
2023-10-26 | Alligator Bioscience AB reports financial results for the first 9 months of 2023 and for Q3 2023 and provides a business update
Downloads
2023-10-12 | Alligator Bioscience Granted New Composition of Matter Patent in Europe for Mitazalimab
Downloads
2023-10-05 | Alligator Bioscience Announces Publication Highlighting ATOR-1017 Preclinical Data in the Scientific Journal “Cancer Immunology, Immunotherapy”
Warning: Attempt to read property “url” on null in /home/alligato/public_html/wp-content/themes/alligator/functions/blog.php on line 287
Downloads
Warning: Attempt to read property “url” on null in /home/alligato/public_html/wp-content/themes/alligator/functions/blog.php on line 287
Downloads
2023-10-03 | Alligator Bioscience to Participate in Upcoming Industry Conferences in October 2023
Downloads
2023-09-28 | Alligator Bioscience Presents New Data Demonstrating Durable Response and Encouraging Anti-Tumor Activity of Lead Asset Mitazalimab
Downloads
2023-09-27 | Alligator Bioscience Announces Publication Highlighting Pharmacodynamic Data from Mitazalimab Phase 1 Study in Scientific Journal “Cells”
Warning: Attempt to read property “url” on null in /home/alligato/public_html/wp-content/themes/alligator/functions/blog.php on line 287
Downloads
Warning: Attempt to read property “url” on null in /home/alligato/public_html/wp-content/themes/alligator/functions/blog.php on line 287
Downloads
2023-09-01 | Alligator receives approximately SEK 13.8 million through the exercise of warrants of series TO 6
Downloads
2023-08-21 | Alligator Bioscience Receives European Medicine Agency Orphan Designation for Mitazalimab in Pancreatic Cancer
Downloads
2023-08-17 | Alligator Bioscience announces resignation of Malin Carlsson as Chief Operating Officer
Downloads
2023-08-15 | Exercise price determined for the exercise of warrants of series TO 6 in Alligator Bioscience AB
Downloads
2023-07-31 | Alligator Bioscience announce milestone achievement in 2021 Immuno-Oncology Research Collaboration and License Agreement with Orion Corporation
Downloads
2023-07-13 | Alligator Bioscience AB reports financial results for H1 2023 and Q2 2023 and provides a business update
Downloads
2023-07-11 | Alligator Bioscience to Present its CD40 Program at the 3rd Annual Tumor Myeloid-Directed Therapies Summit in July 2023
Downloads
2023-07-05 | Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Downloads
2023-06-26 | Alligator Bioscience Announces Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer
Downloads
2023-06-13 | Alligator Bioscience to Host Virtual Key Opinion Leader Event on Mitazalimab Latest Interim Phase 2 Data in 1st Line Metastatic Pancreatic Cancer
Downloads
2023-06-05 | Alligator Bioscience to Present Latest Clinical Data from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer at ASCO Annual Meeting 2023
Downloads
2023-05-26 | Bulletin from the annual general meeting in Alligator Bioscience AB on 26 May 2023
Downloads
2023-05-18 | Alligator Bioscience Receives FDA Orphan Drug Designation for Mitazalimab in Pancreatic Cancer
Downloads
2023-05-11 | Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement
Downloads
2023-04-27 | Alligator Bioscience & Amphera Announce Last Patient Treated in mitazalimab-MesoPher REACTIVE-2 Phase 1 Study in Pancreatic Cancer
Downloads
2023-04-26 | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
Downloads
2023-04-25 | Alligator Bioscience AB reports financial results for Q1 2023 and provides a business update
Downloads
2023-04-18 | Alligator Bioscience Announces Poster Presentation on ATOR-4066 at the AACR Annual Meeting 2023
Downloads
2023-04-12 | Alligator Bioscience Announces Completion of Patient Enrolment in Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer and Confirms Timeline for Top-Line Data in Q1 2024
Downloads
2023-04-03 | Alligator Bioscience Announces FDA Authorization to Initiate Mitazalimab OPTIMIZE-2 Phase 2 Trial in Urothelial Carcinoma
Downloads
2023-03-22 | Alligator intends to carry out a 91 percent secured rights issue of units of approximately SEK 199 million
Downloads
2023-03-14 | Alligator Bioscience Announces KOL Interview on Mitazalimab and the Positive Interim Results from the OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer
Downloads
2023-03-10 | Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Downloads
2023-02-14 | Change in Employee Representatives to the Board of Directors of Alligator Bioscience AB
Downloads
2023-02-13 | Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
Downloads
2023-02-13 | Alligator Bioscience Announces the Promotion of Laura von Schantz to Chief Technology Officer
Downloads
2023-02-10 | Alligator Bioscience AB reports full year financial results for 2022 and for Q4 2022 and provides a business update
Downloads
2023-01-09 | Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences in January and February 2023
Downloads
2023-01-02 | Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate
Downloads
2023-01-02 | Alligator Bioscience and Orion Corporation announce the initiation of the second program of their Immuno-oncology Research Collaboration and License Agreement
Downloads
2022-12-22 | Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal “Investigational New Drugs”
Warning: Attempt to read property “url” on null in /home/alligato/public_html/wp-content/themes/alligator/functions/blog.php on line 287
Downloads
Warning: Attempt to read property “url” on null in /home/alligato/public_html/wp-content/themes/alligator/functions/blog.php on line 287
Downloads
2022-12-13 | Alligator Bioscience to Participate in Upcoming Industry Events in January 2023
Downloads
2022-11-10 | Data presented on mitazalimab and ATOR-1017 in Two Poster Presentations at SITC Annual Meeting 2022 – November 8-12, 2022
Downloads
2022-11-09 | Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
Downloads
2022-11-08 | Alligator Bioscience Announces IND Approval for Second Phase 2 Clinical Trial of AC101 (HLX22) in Gastric Cancer developed by Shanghai Henlius Biotech in China
Downloads
2022-11-02 | Alligator Bioscience Announces Publication Highlighting Bispecific Antibodies Targeting CD40 and Tumor Antigens in Peer-Reviewed Journal for ImmunoTherapy of Cancer
Downloads
2022-11-01 | Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences
Downloads
2022-10-24 | Nomination Committee appointed in respect of AGM 2023 in Alligator Bioscience AB
Downloads
2022-10-20 | Alligator Bioscience AB reports financial results for the first 9 months of the year and for Q3 2022 and provides a business update
Downloads
2022-10-17 | Invitation to the Presentation of Alligator Bioscience´s Interim Report January – September 2022 on October 20, 2022
Downloads
2022-10-10 | Alligator Bioscience to Present at 10th Annual Immuno-Oncology Summit, October 12 -14, 2022
Downloads
2022-09-30 | Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies
Downloads
2022-09-19 | Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a “May Proceed” Notification for the ALG.APV-527 IND
Downloads
2022-09-14 | Alligator Bioscience Presents Additional Data from mitazalimab OPTIMIZE-1 Phase 1b/2 Trial at AACR Special Conference on Pancreatic Cancer 2022
Downloads
2022-09-06 | Alligator Bioscience to Participate in Upcoming Scientific Conferences in September 2022
Downloads
2022-07-12 | Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update
Downloads
2022-05-31 | Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022
Downloads
2022-05-09 | Alligator Bioscience expands its Board of Directors with the appointment of Staffan Encrantz and Denise Goode
Downloads
2022-05-05 | Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022
Downloads
2022-04-22 | Invitation to the Presentation of Alligator Bioscience´s Interim Report January – March 2022 on April 27, 2022
Downloads
2022-04-01 | Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
Downloads
2022-03-23 | Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
Downloads
2022-03-22 | Issue and repurchase of series C shares for performance-based share saving program
Downloads
2022-03-11 | The Nomination Committee’s proposal regarding the Board of Directors ahead of the Annual General Meeting 2022 in Alligator Bioscience AB
Downloads
2022-02-04 | Invitation to the Presentation of Alligator Bioscience´s Year-End Report January – December 2021 on February 11, 2022
Downloads
2022-01-20 | Nomination Committee Appointed in Respect of AGM 2022 in Alligator Bioscience AB
Downloads
2022-01-19 | Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty
Downloads
2022-01-18 | Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported
Downloads
2021-12-16 | Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data
Downloads
2021-12-15 | Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication
Downloads
2021-12-02 | Alligator carries out a directed issue of shares to guarantors in connection with the completed rights issue
Downloads
2021-11-12 | Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021
Downloads
2021-11-12 | Alligator Announces Poster Presentation on Neo-X-Prime™ presenting data on the lead compound targeting CD40 and CEA at SITC Virtual Annual Meeting 2021
Downloads
2021-11-12 | Alligator Announces Poster Presentation on OPTIMIZE-1 at SITC Virtual Annual Meeting 2021
Downloads
2021-11-12 | Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
Downloads
2021-11-08 | Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam
Downloads
2021-11-03 | Nomination Committee appointed in respect of AGM 2022 in Alligator Bioscience AB
Downloads
2021-10-22 | Alligator enters into agreements on subscription commitments with board members and senior executives
Downloads
2021-10-21 | Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc.
Downloads
2021-10-15 | Invitation to the Presentation of Alligator Bioscience´s Interim Report January – September 2021 on October 21, 2021
Downloads
2021-10-07 | Alligator carries out a 100 percent secured rights issue of approximately SEK 257 million
Downloads
2021-09-30 | Alligator Bioscience Announces First Patient Dosed in OPTIMIZE-1 Phase II Clinical Trial Evaluating Mitazalimab in Combination with mFOLFIRINOX for the Treatment of Pancreatic Cancer
Downloads
2021-09-02 | Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline
Downloads
2021-09-02 | Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy
Downloads
2021-08-18 | Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
Downloads
2021-08-16 | Alligator Bioscience Announces New Senior Director of Communications & Investor Relations
Downloads
2021-06-30 | Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data
Downloads
2021-06-07 | Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy
Downloads
2021-06-04 | Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017
Downloads
2021-06-01 | Bulletin from the annual general meeting in Alligator Bioscience AB on June 1, 2021
Downloads
2021-05-04 | Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field
Downloads
2021-04-22 | The Nomination Committee’s proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB
Downloads
2021-04-15 | Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
Downloads
2021-03-11 | Mitazalimab synergizes with chemotherapy – Alligator Bioscience presents new preclinical data at AACR
Downloads
2021-01-21 | Larger shareholder and board member transfer subscription rights free of charge to qualified investors
Downloads
2021-01-11 | The subscription period in Alligator Bioscience’s rights issue commences today
Downloads
2020-12-30 | Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
Downloads
2020-12-28 | Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1
Downloads
2020-12-15 | Alligator carries out a fully guaranteed rights issue of approximately SEK 86m
Downloads
2020-12-10 | Alligator Bioscience launches ALLIGATOR-FAB™ – a novel human antibody library
Downloads
2020-11-20 | Nomination Committee appointed in respect of AGM 2021 in Alligator Bioscience AB
Downloads
2020-11-16 | Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
Downloads
2020-11-05 | Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020
Downloads
2020-09-16 | Alligator Bioscience receives patent approval for the drug candidate ATOR-1015
Downloads
2020-09-09 | Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
Downloads
2020-09-04 | Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study
Downloads
2020-08-25 | Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020
Downloads
2020-06-10 | Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit
Downloads
2020-06-04 | Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology
Downloads
2020-06-01 | Alligator Bioscience’s collaboration with Biotheus Inc. proceeds and second payment is received
Downloads
2020-05-29 | Alligator Bioscience presents novel supportive Phase I data at ASCO for its CTLA-4 x OX40 bispecific drug candidate ATOR-1015
Downloads
2020-05-05 | Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2020
Downloads
2020-04-27 | Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR
Downloads
2020-04-20 | Alligator Bioscience’s Board of Directors reduces its fees and offers possibility for postal voting in front of the Annual General Meeting
Downloads
2020-04-01 | Alligator Bioscience informs about temporary halt of recruitment of new patients due to the covid-19 pandemic
Downloads
2020-03-05 | Alligator Bioscience appoints Andreas Johannesson as interim Chief Financial Officer
Downloads
2019-12-17 | Alligator Bioscience: First patient dosed with ATOR-1017 developed for metastasized cancer
Downloads
2019-11-13 | Nomination Committee appointed in respect of AGM 2020 in Alligator Bioscience AB
Downloads
2019-11-08 | Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
Downloads
2019-11-06 | Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical Data to be presented at SITC 34th Annual Meeting
Downloads
2019-08-20 | Alligator Bioscience signs antibody agreement for Greater China with Biotheus Inc.
Downloads
2019-07-31 | Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107)
Downloads
2019-05-09 | Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on May 9, 2019
Downloads
2019-04-17 | The Nomination Committee’s proposal for the annual shareholders’ meeting in Alligator Bioscience AB (publ)
Downloads
2019-04-11 | Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer
Downloads
2019-04-10 | Alligator Bioscience to present new preclinical data on ATOR-1015 at PEGS Boston
Downloads
2019-04-02 | New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
Downloads
2019-03-18 | New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017
Downloads
2019-02-12 | Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update
Downloads
2019-01-29 | Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer
Downloads
2019-01-07 | Alligator Bioscience launches RUBY™, a novel concept in bispecific antibody formats
Downloads
2018-11-09 | Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Downloads
2018-11-07 | Alligator Bioscience to receive million-dollar payments – AbClon partner exercises option
Downloads
2018-11-06 | Nomination Committee appointed in respect of AGM 2019 in Alligator Bioscience AB
Downloads
2018-10-30 | Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144
Downloads
2018-09-28 | New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017
Downloads
2018-08-30 | Alligator Bioscience presents at the 20th Annual Rodman & Renshaw Global Investment Conference
Downloads
2018-07-19 | Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
Downloads
2018-06-21 | Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells
Downloads
2018-05-16 | Invitation to Alligator Bioscience Capital Markets Day in Stockholm on May 29, 2018
Downloads
2018-05-08 | New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics
Downloads
2018-04-26 | Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on 26 April 2018
Downloads
2018-04-18 | Save the date: Alligator Bioscience to host Capital Markets Day in Stockholm on 29 May 2018
Downloads
2018-04-17 | Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation
Downloads
2018-04-05 | Alligator Bioscience presents at the H.C. Wainwright Annual Global Life Sciences Conference
Downloads
2018-02-12 | Alligator Bioscience to Host Conference Call to Provide Full Year Report 2017 Business Update
Downloads
2018-01-25 | Alligator Bioscience contracts Theradex Oncology as clinical CRO for the upcoming ATOR-1015 phase I study
Downloads
2018-01-04 | Alligator Bioscience to Present at the 10th Annual Biotech Showcase Conference
Downloads
2018-01-03 | Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013
Downloads
2017-11-21 | Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017
Downloads
2017-11-13 | Nomination Committee appointed in respect of AGM 2018 in Alligator Bioscience AB
Downloads
2017-11-07 | Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013
Downloads
2017-10-24 | Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527
Downloads
2017-09-21 | Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017
Downloads
2017-09-13 | Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB
Downloads
2017-08-23 | Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017
Downloads
2017-08-17 | Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527
Downloads
2017-07-21 | Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy
Downloads
2017-06-12 | Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development
Downloads
2017-05-04 | Alligator Bioscience presents promising immuno-oncology data at US conference; – Strong new preclinical findings for ADC-1013 and ATOR-1015
Downloads
2017-05-02 | Bulletin from the annual shareholders’ meeting in Alligator Bioscience AB (publ) on May 2, 2017
Downloads
2017-04-28 | Alligator Bioscience to present new pre-clinical data for ADC-1013 and ATOR-1015 at PEGS conference in Boston, May 4
Downloads
2017-03-23 | Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013
Downloads
2017-02-15 | Conference call for investors, analysts and the media on Friday, February 17 in connection with the company’s Full Year Report
Downloads
2016-12-23 | Exercise of over-allotment option and notice of stabilisation in Alligator Bioscience
Downloads
2016-11-14 | Alligator Bioscience AB publishes prospectus for Initial Public Offering on Nasdaq Stockholm
Downloads